Top Page
Recce Pharmaceuticals Ltd.
(Sydney:RCE)
Recce Pharmaceuticals Ltd. (RCE) vs. iShares MSCI Australia ETF (EWA)
Recce Pharmaceuticals Ltd. Business Overview & Revenue Model
Recce Pharmaceuticals Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.51M | 7.51M | 5.03M | 4.37M | 3.08M | 1.64M |
| Gross Profit | -2.94M | -2.94M | -2.19M | 4.15M | 2.90M | 1.34M |
| EBITDA | -20.28M | -20.33M | -21.35M | -16.99M | -13.87M | -14.77M |
| Net Income | -21.43M | -21.43M | -17.66M | -13.08M | -10.99M | -13.51M |
Balance Sheet | ||||||
| Total Assets | 12.41M | 12.41M | 6.37M | 2.56M | 12.62M | 21.68M |
| Cash, Cash Equivalents and Short-Term Investments | 10.45M | 10.45M | 4.42M | 1.56M | 11.58M | 20.87M |
| Total Debt | 10.77M | 10.77M | 811.19K | 250.57K | 74.76K | 126.95K |
| Total Liabilities | 15.47M | 15.47M | 15.89M | 5.14M | 2.56M | 1.18M |
| Stockholders Equity | -3.05M | -3.05M | -9.52M | -2.59M | 10.06M | 20.50M |
Cash Flow | ||||||
| Free Cash Flow | -20.47M | -20.47M | -13.15M | -12.73M | -9.05M | -7.93M |
| Operating Cash Flow | -20.44M | -20.44M | -13.01M | -12.69M | -9.01M | -7.86M |
| Investing Cash Flow | -443.90K | -443.90K | -141.90K | -38.63K | -40.34K | -76.01K |
| Financing Cash Flow | 26.92M | 26.92M | 16.00M | 2.71M | -240.50K | 26.12M |
Recce Pharmaceuticals Ltd. Technical Analysis
Recce Pharmaceuticals Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$90.43M | -9.45 | -49.72% | ― | ― | 10.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$64.13M | ― | -27.39% | ― | ― | 26.64% | |
44 Neutral | AU$160.50M | ― | ― | ― | ― | 0.66% | |
41 Neutral | AU$97.88M | ― | -42.68% | ― | ― | 63.46% | |
41 Neutral | $104.06M | ― | -83.09% | ― | ― | 55.94% | |
40 Underperform | AU$106.68M | -13.09 | -47.98% | ― | 700.00% | 26.88% |
Recce Pharmaceuticals Ltd. Corporate Events
Recce Pharmaceuticals Ltd. announced the granting of a patent in Hong Kong for its anti-infective products, RECCE® 327 and RECCE® 529, which are used to treat various infections. This patent strengthens Recce’s intellectual property portfolio in Asia, supporting its strategy to enter markets with significant medical and commercial potential, such as the ASEAN region, where it is also progressing with a Phase 3 clinical trial in Indonesia.
Recce Pharmaceuticals Ltd. announced positive preclinical results for its synthetic anti-infective, RECCE® 327, in treating hospital-acquired pneumonia caused by multidrug-resistant Acinetobacter baumannii in mice models. The study demonstrated that nebulised R327 significantly reduced bacterial load in the lungs, outperforming traditional antibiotics like meropenem, which face solubility challenges. This advancement highlights R327’s potential as a critical treatment option in hospital settings, particularly for drug-resistant lung infections, and underscores its versatility and efficacy in direct lung delivery.
Recce Pharmaceuticals Ltd. announced the passing of its founder, Dr. Graham JH Melrose, a pioneer in polymer chemistry and infectious diseases. His leadership and vision were instrumental in establishing Recce as a notable player in the biotech industry, focusing on innovative solutions to antibiotic resistance. Dr. Melrose’s legacy continues to inspire the company’s mission and future innovations.
Recce Pharmaceuticals Ltd held its 2025 Annual General Meeting, where all resolutions were decided by poll. Notably, the re-election of Dr. John Prendergast and Dr. Justin Ward as directors was carried, while resolutions related to the future issue of securities and ratification of prior share and warrant issues were not carried. The outcome of the meeting, including a ‘first strike’ against the remuneration report, may impact the company’s governance and future strategic decisions.
Recce Pharmaceuticals Ltd presented at their Annual General Meeting in 2025, highlighting their strategic intentions and future plans. The presentation emphasized the company’s commitment to innovation in the pharmaceutical sector, particularly in combating antibiotic resistance. While the document outlines potential future strategies, it also acknowledges the inherent risks and uncertainties that could impact the company’s performance and operations.
Recce Pharmaceuticals Ltd has commenced patient dosing in a Phase 3 clinical trial for diabetic foot infections in Indonesia, aiming to enroll up to 310 patients. This trial is significant due to Indonesia’s high diabetes prevalence and the urgent need for new treatment solutions. The company’s RECCE® 327 Topical Gel has shown high efficacy against antibiotic-resistant pathogens, highlighting its potential impact on the treatment of chronic wounds and positioning Recce as a key player in addressing global health challenges.
Recce Pharmaceuticals Ltd announced a change in the director’s interest, specifically concerning James Graham, who has disposed of 745,962 Class B Performance Shares through a selective buy-back approved by shareholders. This change reflects a strategic adjustment in the company’s equity structure, potentially impacting its market positioning and shareholder value.
Recce Pharmaceuticals Ltd has announced the cessation of 8,754,423 performance shares due to a selective buy-back, effective October 7, 2025. This move may impact the company’s capital structure and could be part of a strategic effort to optimize shareholder value and streamline operations, signaling potential shifts in their market positioning.
Recce Pharmaceuticals Ltd has announced the final notification of its selective buy-back of performance shares, totaling 8,754,423 securities at a consideration of AUD 87.54. This strategic move is likely to impact the company’s financial structure and could influence its market positioning by potentially increasing shareholder value.
Recce Pharmaceuticals Ltd has announced an update regarding its selective buy-back of performance shares, identified by the ASX security code RCEAH. The update pertains to the date of the buy-back occurring, which has been changed from the initially notified date. This announcement could impact stakeholders by altering the timeline of the buy-back process, potentially affecting the company’s share structure and market perception.
Recce Pharmaceuticals Ltd announced the dispatch of documents related to its 2025 Annual General Meeting to shareholders. The company’s innovative anti-infective solutions, which have garnered significant recognition, position it as a key player in addressing global health challenges related to antibiotic resistance. The upcoming meeting is set to discuss these advancements and their implications for stakeholders.
Recce Pharmaceuticals has commenced patient dosing in its Registrational Phase 3 clinical trial for diabetic foot infections (DFI) in Indonesia, with five clinical sites activated. This trial, one of the largest DFI studies globally, aims to assess the efficacy of RECCE 327 Topical Gel (R327G) and is expected to have interim results by Q1 2026. The trial is strategically significant given Indonesia’s high diabetes prevalence, representing a substantial market opportunity. Successful results could lead to accelerated approval and a potential commercial launch in 2026, positioning Recce as a key player in addressing diabetes-related infections.
Recce Pharmaceuticals Ltd has announced its Annual General Meeting scheduled for November 5, 2025, with the closing date for director nominations set for September 23, 2025. This announcement underscores the company’s ongoing commitment to advancing its anti-infective pipeline, which has garnered significant attention from global health authorities for its potential to address critical health challenges posed by resistant pathogens.